Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

711
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
711
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

74.8K
Overview
74.8K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

3.7K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Elevated IL-6 receptor expression on CD4+ T cells contributes to the increased Th17 responses in patients with chronic hepatitis B.

Virology journal·2011
Same author

Neurochemical plasticity of nitric oxide synthase isoforms in neurogenic detrusor overactivity after spinal cord injury.

Neurochemical research·2011
Same author

[Clinical significance of 5-HT and DA levels in serum and cerebrospinal fluid of the patients with delayed encephalopathy after acute carbon monoxide poisoning].

Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases·2011
Same author

Reconstitution of lysosomal NAADP-TRP-ML1 signaling pathway and its function in TRP-ML1(-/-) cells.

American journal of physiology. Cell physiology·2011
Same author

[The association between HBV genotyping and clinical characteristics and expression of TH1/TH2 cytokines].

Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology·2011
Same author

Bis[5-(2-pyrid-yl)pyrazine-2-carbonitrile]-silver(I) tetra-fluorido-borate.

Acta crystallographica. Section E, Structure reports online·2011

Related Experiment Video

Updated: Oct 4, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

TCR-T Immunotherapy: The Challenges and Solutions.

Yating Liu1,2, Xin Yan2, Fan Zhang2

  • 1Department of Oncology, Lanzhou University Second Hospital, Lanzhou, China.

Frontiers in Oncology
|February 11, 2022
PubMed
Summary

T cell receptor-engineered T cell (TCR-T) therapy shows promise for solid tumors, overcoming surface antigen limits. This review explores barriers and strategies to improve TCR-T cell immunotherapy efficacy in solid tumors.

Keywords:
challengesimmunotherapyreceptor-engineered T cellsolid tumorssolutions

More Related Videos

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

12.0K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.0K

Related Experiment Videos

Last Updated: Oct 4, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

12.0K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.0K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • T cell receptor-engineered T cell (TCR-T) therapy offers a potential cancer treatment by targeting intracellular antigens, independent of surface expression.
  • Advances in treating blood cancers with cellular immunotherapies have spurred interest in applying TCR-T cell therapy to solid tumors.

Purpose of the Study:

  • To identify and analyze the key barriers hindering the efficacy of TCR-T cell immunotherapy in solid tumors.
  • To discuss strategies aimed at enhancing the effectiveness of TCR-T cell immunotherapy for solid tumor treatment.

Main Methods:

  • Literature review and analysis of existing research on TCR-T cell therapy in solid tumors.
  • Identification of challenges and proposed solutions based on current scientific understanding.

Main Results:

  • TCR-T cell therapy faces significant challenges in solid tumors compared to hematological malignancies.
  • Several factors limit the overall efficacy, necessitating targeted strategies for improvement.

Conclusions:

  • Overcoming the identified barriers is crucial for realizing the full potential of TCR-T cell immunotherapy in solid tumors.
  • This review provides a reference for researchers to enhance TCR-T cell therapy effectiveness against solid cancers.